A Study of FCN-338 in Patients With Chronic CLL/SLL
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the TolerabilityćPharmacokinetics and Preliminary
antitumor activity of oral FCN-338 for the treatment of patients with chronic lymphocytic
leukemia (CLL) or small lymphocytic lymphoma (SLL), who have failed or are intolerant to one
or more lines of established therapy or for whom no other treatment options are available.